Digital pathology
Paige
Digital pathology AI applications for cancer pathology, including Paige Prostate.
Last updated: May 25, 2026
Back to directoryProscia medical AI product profile
Concentriq digital pathology platform that supports diagnostic, research, and AI-enabled pathology workflows.
Digital pathology
Best fit
Organizations building an enterprise digital pathology foundation that can connect image management, AI apps, and data workflows.
- Primary use case
- Digital pathology image management, AI application deployment, model development, and lab workflow orchestration
- Audience
- Anatomic pathology labs, academic medical centers, life-sciences teams, and digital pathology operations leaders
- Risk level
- High
- Pricing signal
- Enterprise pricing; request current terms.
- Official sources
- 6 official sources
Compare within workflow: Digital pathology · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
product-specific source-backed lens: These product-specific signals summarize what the cited sources imply before treating Proscia as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Separate Concentriq AP-Dx primary-diagnosis clearance from Concentriq AP, Concentriq LS, third-party AI applications, and research workflows; scanner and specimen limitations matter. |
|---|---|
| Privacy | Confirm hosting, storage, scanner ingestion, LIS integration, user roles, collaboration access, retention, audit logs, and contract terms for diagnostic and life-sciences deployments. |
| Evidence | Review the multi-site primary-diagnosis study and any AI-application evidence against the lab's scanner, tissue, specimen, pathologist, and workload context. |
| Workflow | Best evaluated as a digital-pathology operating layer where primary diagnosis, AI launch, collaboration, and data-science workflows each need separate governance. |
Where Proscia fits
Proscia describes Concentriq as an enterprise pathology platform for digital pathology, AI applications, data science, diagnostics, and life-sciences workflows; Concentriq AP-Dx materials describe FDA 510(k) clearance for primary diagnosis with a specified scanner, while other platform and AI components may have research-use limits.
Not for: Assuming every connected AI application is cleared for diagnosis without separate intended-use and validation review.
What to verify before using Proscia
- Whether Concentriq AP, Dx, LS, or another deployment model fits the lab setting.
- Regulatory and intended-use status for each AI application in the workflow.
- Scanner, LIS, storage, viewer, and interoperability requirements.
- Governance for third-party AI apps, model outputs, and pathologist signout.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- proscia.com / concentriq-platform
- proscia.com / concentriq-ap-dx
- proscia.com / ai
- proscia.com / concentriq-dx
- proscia.com / press-releases / proscia-receives-fda-510k-clearance-for-concentriq-ap-dx-2
- proscia.com / wp-content / uploads
Related medical AI products
Digital pathology
Digital pathology
PathAI
AI-enabled digital pathology platform with image management and algorithm access.
Digital pathology
Ibex Medical Analytics
Clinical-grade AI pathology platform for cancer diagnostics and pathology workflow support.
Digital pathology
Aiforia
AI pathology platform with clinical suites for whole-slide image workflows, quantitative overlays, and pathologist review.